Phasebio pharmaceuticals inc (PHAS)
Income statement / Quarterly
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Sep'17
Revenue:
Grant revenue

320

764

241

703

653

-

411

-

-

-

Operating expenses:
Research and development

11,449

8,381

9,028

7,781

5,721

5,676

4,354

3,190

2,235

1,330

General and administrative

3,159

3,663

2,803

2,404

2,316

2,241

1,056

917

643

565

Total operating expenses

14,608

12,044

11,831

10,185

8,037

7,917

5,410

4,107

2,878

1,895

Loss from operations

-14,288

-11,280

-11,590

-9,482

-7,384

-7,660

-4,999

-4,107

-2,878

-1,895

Other income (expense):
Loss from remeasurement of development derivative liability

-454

-

-

-

0

-

-

-

-

-

Interest income

211

323

451

491

317

255

60

36

36

14

Interest expense

378

365

266

219

226

183

890

1,447

1,404

618

Foreign exchange gain

4

-9

14

-22

0

-

-

-

-

-

Fair Value Adjustment of Warrants

-

-

-

-

-

-2,720

1,713

1,001

-5

-5

Unrealized Gain (Loss) on Derivatives

-

-

-

-

-

0

-359

-155

-162

-66

Total other income (expense)

-617

-51

199

250

91

2,792

-2,902

-2,567

-1,525

-665

Net loss

-14,905

-11,331

-11,391

-9,232

-7,293

-4,868

-7,901

-6,674

-4,403

-2,560

Net loss per common share, basic and diluted (in usd per share)

-0.52

-0.40

-0.40

-0.33

-0.30

20.81

-10.45

-8.95

-5.90

-3.44

Weighted average common shares outstanding, basic and diluted (in shares)

28,773

28,823

28,719

27,932

24,498

18,972

755

745

745

743

Grant revenue
Total revenue

-

-

241

203

-

-

411

-

-

-

Revenue under collaborative agreement
Total revenue

-

-

-

500

-

-

-

-

-

-